Invitris
Invitris radically simplifies how we create novel biological drugs. Our patent-pending technology platform turns DNA into synthetic proteins and was recently featured in the Science magazine. It makes creating new drugs >10,000x more efficient at <100x lower costs of material. Our killer application is enabling the newest generation of synthetic bacteriophages to combat antibiotic-resistant infections, which are threatening to cause more deaths than all cancers combined.
Y Combinator
yc-company-directory #5185Invitris radically simplifies how we create novel biological drugs. Our patent-pending technology platform turns DNA into synthetic proteins and was recently featured in the Science magazine. It makes creating new drugs >10,000x more efficient at <100x lower costs of material. Our killer application is enabling the newest generation of synthetic bacteriophages to combat antibiotic-resistant infections, which are threatening to cause more deaths than all cancers combined.
sourceInvitris is classified as AI infrastructure from source descriptions and fund-directory context. Similar companies below are ranked from offline product facets and meaningful description overlap; category and source affiliation can only strengthen an existing product match. For lookup-created rows, the profile starts as pending enrichment until deeper source collection runs.
Local clusters rerank extracted product concepts and description terms. The generated graph remains the fallback for sparse descriptions: offline reciprocal product-similarity graph: extracted concepts + description terms + bounded category/affiliation boosts. Minimum fallback score: 0; max competitors: 6.
Companies similar to Invitris
A deterministic local cluster built from offline product facets and meaningful description terms. Category and selected-institution affiliation provide bounded tie-breaks. Open any peer to continue exploring its cluster.
GEn1E Lifesciences
match 52GEn1E Lifesciences is a Clinical-stage, multi-target company with a unique AI platform. We develop novel, next-generation, immunomodulatory therapies for rare & inflammatory diseases with no effective treatments. Our team is supercharging the drug development cycle by applying AI to multiple-mechanism-of-action protein targets and their natural platform capabilities—creating novel therapeutics at an unprecedented pace. Our AI platform has enabled us to develop a purpose-built therapy for ARDS to
shared product terms: novel, generation, drug, protein; same category: AI infrastructure; shared affiliation: Y Combinator
Flightcaster
match 48FlightCaster predicts flight delays. FlightCaster can predict your probability of delay hours before the airline or any other app notifies you. FlightCaster uses a patent-pending algorithm that scours data on every domestic flight for the past 10-years and matches it to real-time conditions.
shared extracted concept terms: patent, pend; shared product terms: patent, pend, 10; same category: AI infrastructure; shared affiliation: Y Combinator
NATIX
match 44We make any camera smart and 100% privacy compliant! Utilising our patent-pending technology, we are creating the largest crowd-sourced camera network worldwide.
shared extracted concept terms: patent, pend; shared product terms: patent, pend, creat
Evolvere BioSciences
match 44🦠🤖 We use our computational models to make next-generation antibiotics that outcompete bacterial evolution and precisely target pathogenic bacteria, without harming good microbes or human cells. ☠️ Current antibiotics stop working because bacteria evolve resistance to them. This makes drug-resistant bacteria a looming global health crisis - already killing more people than malaria and AIDS and it is getting exponentially worse 📈. 🧬 Our approach leverages co-evolutionary protein-protein inter
shared product terms: generation, antibiotic, drug, resistant; same category: AI infrastructure; shared affiliation: Y Combinator
D-ID
match 38D-ID enables creators and developers to generate realistic high-quality AI personas easily and ethically through the use of our platform and APIs, based on deep-learning and AI-powered technology - Enabling Creative Reality™. D-ID is a Tel Aviv-based Creative Reality™ startup specializing in patented video reenactment technology using AI and deep learning. Established in 2017, D-ID created the first facial image de-identification solution to protect images and videos from facial recognition soft
shared extracted concept terms: patent; shared product terms: enabl, patent, creat; same category: AI infrastructure; shared affiliation: Y Combinator
Narval
match 27Synthetic Antibody Mimetic Proteins for novel first-in-class immunotherapeutics
shared product terms: synthetic, protein, novel; same category: AI infrastructure